Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

AI models may amplify bias in psychiatric aggression predictions

7

Apr 2026

AI models may amplify bias in psychiatric aggression predictions

A first-of-its-kind study led by researchers at the Centre for Addiction and Mental Health (CAMH) has found that artificial intelligence (AI) models used to predict aggressive incidents in acute psychiatric care can reinforce and amplify existing social and structural inequities by overestimating the likelihood of aggression among already marginalized groups.

What happens in the brain on psychedelics? Scientists identify a common circuit pattern

7

Apr 2026

What happens in the brain on psychedelics? Scientists identify a common circuit pattern

Researchers combined 11 international resting-state fMRI datasets to map how psychedelic drugs reshape brain connectivity across cortical and subcortical circuits. The mega-analysis found a shared signature of stronger coupling between transmodal association networks and unimodal or sensorimotor systems, alongside selective and variable reductions in within-network connectivity.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.